Zinc binding groups for histone deacetylase inhibitors
Zinc binding groups (ZBGs) play a crucial role in targeting histone deacetylase inhibitors (HDACIs) to the active site of histone deacetylases (HDACs), thus determining the potency of HDACIs. Due to the high affinity to the zinc ion, hydroxamic acid is the most commonly used ZBG in the structure of...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Book |
| Published: |
Taylor & Francis Group,
2018-01-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
| LEADER | 00000 am a22000003u 4500 | ||
|---|---|---|---|
| 001 | doaj_1b9ebe75b9b14979aff1e37a1d0b2fff | ||
| 042 | |a dc | ||
| 100 | 1 | 0 | |a Lei Zhang |e author |
| 700 | 1 | 0 | |a Jian Zhang |e author |
| 700 | 1 | 0 | |a Qixiao Jiang |e author |
| 700 | 1 | 0 | |a Li Zhang |e author |
| 700 | 1 | 0 | |a Weiguo Song |e author |
| 245 | 0 | 0 | |a Zinc binding groups for histone deacetylase inhibitors |
| 260 | |b Taylor & Francis Group, |c 2018-01-01T00:00:00Z. | ||
| 500 | |a 1475-6366 | ||
| 500 | |a 1475-6374 | ||
| 500 | |a 10.1080/14756366.2017.1417274 | ||
| 520 | |a Zinc binding groups (ZBGs) play a crucial role in targeting histone deacetylase inhibitors (HDACIs) to the active site of histone deacetylases (HDACs), thus determining the potency of HDACIs. Due to the high affinity to the zinc ion, hydroxamic acid is the most commonly used ZBG in the structure of HDACs. An alternative ZBG is benzamide group, which features excellent inhibitory selectivity for class I HDACs. Various ZBGs have been designed and tested to improve the activity and selectivity of HDACIs, and to overcome the pharmacokinetic limitations of current HDACIs. Herein, different kinds of ZBGs are reviewed and their features have been discussed for further design of HDACIs. | ||
| 546 | |a EN | ||
| 690 | |a Histone deacetylase inhibitor | ||
| 690 | |a zinc binding group | ||
| 690 | |a anti-tumour | ||
| 690 | |a selectivity | ||
| 690 | |a drug design | ||
| 690 | |a Therapeutics. Pharmacology | ||
| 690 | |a RM1-950 | ||
| 655 | 7 | |a article |2 local | |
| 786 | 0 | |n Journal of Enzyme Inhibition and Medicinal Chemistry, Vol 33, Iss 1, Pp 714-721 (2018) | |
| 787 | 0 | |n http://dx.doi.org/10.1080/14756366.2017.1417274 | |
| 787 | 0 | |n https://doaj.org/toc/1475-6366 | |
| 787 | 0 | |n https://doaj.org/toc/1475-6374 | |
| 856 | 4 | 1 | |u https://doaj.org/article/1b9ebe75b9b14979aff1e37a1d0b2fff |z Connect to this object online. |